Abstract: The invention provides a phototherapy device that includes a controlled environment defined by a plurality of transparent panels and at least one light emitting diode portion that projects light into the controlled environment.

Abstract: The invention relates to a motion determination apparatus for determining motion of a moving object, wherein the motion determination apparatus (1) comprises a multi-axial accelerometer (2) for being positioned at the moving object (4), wherein the multi-axial accelerometer (2) is adapted to generate accelerometer signals indicative of the acceleration along different spatial axes. The motion determination apparatus further comprises a motion signal generation unit (3) for generating a motion signal indicative of the motion of the object (4) by combining the accelerometer signals of different spatial axes. The combination of the accelerometer signals of different spatial axes yields a motion signal having a large signal-to-noise ratio, even if an axis is located close to a rotational axis of the movement.

Abstract: An antibody specifically binding to human thymic stromal lymphopoietin receptor (TSLPR), characterized in comprising as heavy chain variable domain CDR regions a CDR1 region of SEQ ID NO:2 or 17, a CDR2 region of SEQ ID NO:3 or 10, and CDR3 region of SEQ ID NO:4, and as light chain variable domain CDR regions a CDR1 region of SEQ ID NO:6 or 12, a CDR2 region of SEQ ID NO:7, 13 or 15, and a CDR3 region of SEQ ID NO:8. is useful for the treatment of immunological diseases.

Abstract: Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.

Abstract: Compounds of formula I are disclosed. These compounds are useful in the control or prevention of cancer.

Abstract: An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between CH1 and CH2 and/or in the second inter-domain region at amino acid position 327-331 between CH2 and CH3 has advantageous properties for the treatment of inflammatory diseases.

Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: A method for monitoring the blood pressure of a patient, comprising the following steps: determining a pulse arrival time signal from the patient 2 based on the pulse wave velocity method; determining an accelerometer signal from the patient 2; and triggering an additional measure or deriving a blood pressure value, taking into account the pulse arrival time signal and a DC component of the accelerometer signal. In this way, a possibility for monitoring the blood pressure of a patient is provided with which false alarms and/or unnecessary additional cuff-based blood pressure measurements can be avoided.

Abstract: Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Abstract: The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between CH1 and CH2 and/or in the second inter-domain region at amino acid position 327-331 between CH2 and CH3 has advantageous properties for the treatment of inflammatory diseases.

Abstract: Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.

Abstract: Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Abstract: Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Abstract: The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of such compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

Abstract: Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Abstract: The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

Abstract: A method for accelerating a pseudo-random input bit flow (PRBS(T1)), generated at a first relatively low dock frequency (f1), into an identical output bit flow (PRBS(T0)) at a second relatively high dock frequency (f0), comprising: collecting the output bit flow, delaying the collected flow by a predetermined value (?); and combining the delayed flow with the input bit flow.